ACIP Crafts Plan For DTaP Shortage.(Brief Article)
ATLANTA -- Infants receiving their first three doses of diphtheria-tetanus-acellular pertussis vaccine should be given first priority if a shortage of DTaP vaccine develops in the next few months, members decided at a meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.
In late 2000, two of the four United States manufacturers of DTaP vaccine--Wyeth-Lederle and Baxter Hyland Immuno--announced that they were ceasing production of Acel-Imune and Certiva, respectively. That leaves just two DTaP vaccines licensed for the U.S. market: Aventis-Pasteur's Tripedia and Glaxo SmithKline's Infanrix.
There is no major shortage of DTaP currently, but the CDC's National Immunization Program is taking steps now to prioritize use of the vaccine in case the supply falls short in …
Related articles on HighBeam Research
The Turkish Journal of Pediatrics; November 1, 2010
Nursing Education Perspectives; January 1, 2004
Human Resources for Health; July 31, 2007
Vaccine Weekly; July 6, 2011
CMAJ: Canadian Medical Association Journal; March 4, 2003
Publication Finder
Browse back issues from our extensive library of more than 6,500 trusted publications.
Popular publicationson HighBeam Research
Help us improve our websites
Become a member of our Customer Advisory Panel. Your opinion matters!
Join the panel